APPLICATION OF COMBINED NEUROPROTECTION IN DIABETIC PATIENTS WITH ACUTE STROKE
Keywords:
acute ischemic stroke, diabetes mellitus, neuroprotection, cytocholine, magnesium sulfateAbstract
One of the main causes and an important risk factor for acute stroke (AS) is diabetes mellitus (DM), which aggravates the course of a stroke, increases the risk of complications and fatal outcome. Neuroprotectors are now widely used to reduce neurological deficits and improve the results of AS treatment. Aim: to investigate the effectiveness of citicoline and magnesium sulfate as a combined neuroprotective therapy in patients with acute stroke with concomitant diabetes mellitus. The comprehensive clinical-neurological and laboratory examination was carried out of 346 patients (171 women and 175 men) who suffered acute ischemic stroke with and without such carbohydrate metabolic disorders (main groups). In the main groups of patients, as a neuroprotective agent, citicoline 1000 mg 1 time per day was administered and a solution of magnesium sulfate 25% 30 ml per day in 2–3 injections. To determine the effectiveness of the developed scheme of intensive care, a separate group (36 patients — 16 women and 20 men) was selected, in which treatment was carried out according to the traditional approach (control group). In the control group various preparations with the declared manufacturer neuroprotective action (except for citicoline and magnesium sulfate) were used. The combination of citicoline with magnesium sulfate was reliably effective in treating patients with AS against the background of concomitant diabetes. In patients without diabetes, the effectiveness of this combination was lower, and in the group of patients who received the traditional treatment of significant differences in the dynamics of clinical and laboratory parameters was not found.
References
Парфенов В. А., Хасанова Д. Р. Ишемический инсульт. М. : ООО «Издательство «Медицинское информационное агенство», 2002, 288 с.
Сучасні принципи діагностики та лікування хворих із гострим ішемічним інсультом та ТІА (Адаптована клінічна настанова). К., Видавець Д. В. Гуляєв, 2012. 144 с.
Стаднік С. М. Сучасні підходи до превентивно-терапевтичної корекції постінсультних когнітивних розладів. Гострі та невідкладні стани в практиці лікаря. 2017; 1(64): 32–38.
Overgaard K. The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. 2014 Aug; 23(7): 1764-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.020.
Alvarez-Sabin J., Roman G. C. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013 Sep 23; 3(3): 1395-414. doi: 10.3390/brainsci3031395.
Nomani F., Kamal A. K. Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial) is the use of Citicoline is beneficial for acute ischaemic stroke? J Pak Med Assoc. 2013 Nov; 63(11): 1445. PubMed PMID: 24392540.
Титов И. И. Эффективность, безопасность и переносимость комбинации электролитов и цитиколина (Нейроцитин®) у пациентов с острым ишемическим инсультом: первые результаты исследования. Міжнар. невролог. журнал. 2017; 1(87): 64–72.
Гельфанд Б. Р., Салтанов А. И. (ред.). Интенсивная терапия: национальное руководство: в 2-х т. М. : ГЭОТАР-Медиа, 2009. Т. I, 960 с.
Соколова Л. І., Довбонос Т. А., Шандюк В. Ю. Застосування сульфату магнію при ішемічному інсульті. Укр. невролог. журнал. 2015; № 4(37): 91–97.
Singh H., Jalodia S., Gupta M. S., Talapatra P., Gupta V., Singh I. Role of magnesium sulfate in neuroprotection in acute ischemic stroke. Ann Indian Acad Neurol. 2012 Jul; 15(3): 177-80. doi: 10.4103/0972-2327.99705.
Afshari D., Moradian N., Rezaei M. Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clin Neurol Neurosurg. 2013 Apr; 115(4): 400-4. doi:10.1016/j. lineuro.2012.06.001.
